In addition, antibodies against IGF-II have been developed [122] and may have potential for PF treatment in view of the data showing that IGF-II tips the balance of fibrotic factors, extracellular matrix components, and enzymes responsible for ECM processing and degradation in favor of fibrosis. This evidence concerns the gene IGF2 and pemphigus foliaceus.